NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In BioMedWire Editorial On Biotech Valuation Shift
Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how advancing drug pipelines are reshaping biotech valuations, as scientific progress is increasingly recognized as a measurable financial asset under evolving accounting frameworks. The piece highlights Oncotelic’s position at the intersection of oncology and AI-driven drug development, noting its diversified pipeline and strategic holdings, including a 45% stake in GMP Bio, as examples of how innovation and clinical advancement are being reflected in tangible enterprise value. To view the full press release, visit https://nnw.fm/0p33P About Oncotelic Therapeutics Inc. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is…







